argenx has agreed to acquire the remaining shares of Unnatural Products (UNP), a biotech it already partly owns, in a deal worth up to about $1.15 billion.
The terms include $550 million in cash upfront and up to $595 million in development and regulatory milestone payments.
The acquisition would bring UNP’s macrocyclic-peptide discovery platform in-house, complementing argenx’s antibody capabilities and potentially broadening its pipeline of oral or long-acting treatments for immune-mediated diseases.
UNP’s team is expected to remain in Santa Cruz, California, which would become argenx’s peptide-discovery hub. The companies said they expect the deal to close by year-end, subject to customary conditions.
The move builds on a research collaboration between the companies. Macrocyclic peptides are being explored for targets that can be difficult to reach with conventional medicines, though the deal’s therapeutic benefits remain prospective.
Sources:
sec-gov-archives-edgar-data-1697862-000110465926124060-tm2629301d2-ex99-1-htm
Argenx to Buy US Biotech for $1.15 Billion to Gain Peptides
Argenx to acquire Unnatural Products for $1.15B
DLA Piper Steers Argenx On Up To $1.15B Deal For Biotech
Argenx inks $1.15B Unnatural Products buyout for oral ...
AI-Guided Macrocycle Discovery Lands at argenx in $1.15B Deal | Pharmaceutical Technology
Argenx to Buy Unnatural Products for Up to $1.15 Billion
Argenx to acquire biotech firm Unnatural Products for $1.15 billion
argenx to Acquire Unnatural Products in Deal Valued at Up to $1.15 Billion
BRIEF-Argenx To Acquire Unnatural Products, Inc.
Argenx to buy Unnatural Products in 1.15 bln usd deal